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INTRODUCTION
Tuberculosis (TB) is the leading cause of death and it caused by 
Mycobacterium TB. TB has been known for 5000 years, and the 
morbidity and mortality rate is high and yet goes on. Despite the fact 
that World Health Organization in its attempt to control TB declared 
as Global emergency in 1993, TB is still highly mortal. It is the second 
leading cause of adult death. In India, approximately 4.81 thousand 
people are suffering from TB [1]. In 2016, there were >10 million 
instances of active TB, which resulted in 1.3 million deaths. >90% of 
death taking place in growing nations.
Weight loss is the major fundamental sign and general symptoms 
include fever, shivering, loss of appetite, and tiredness. The treatment 
of active Tb was available from half a century.
The observation of micronutrient deficiencies in adults with TB led to 
intervention studies and to explore whether replacing would improve 
patients’ recovery [2]. Zinc (Zn) deficiency affects host defense by 
detaining phagocytosis and reducing the number of T cells. Zn has a 
very prominent part in cell-mediated immune function and likewise 
serve as anti-inflammatory and antioxidant in TB [3-6].
Several studies have shown that the serum levels of Zn decrease 
significantly during active TB and increase the following recovery after 
the institution of anti-TB therapy and improvement of the nutritional 
status [7-9].
Subject selection and methodology
The above study was performed in the department of pulmonology 
in one public hospital in Chennai, Tamil Nadu, from August 2017 
to April 2018. The studies were picked out along the basis of the 
following criteria: Age above 18 years, three sputum specimens 
which are positive for acid-fast bacilli by direct microscopy 
and culture, and consistent by clinical and radiologic signs with 
pulmonary TB (PTB), and no state of past anti-TB treatment. In 
exclusion criteria were patients who are diagnosed with extra-PTB 
and with multidrug-resistant TB and extensively drug-resistant TB; 
pregnant and nursing women; and diagnosed with IBD and lung 
carcinoma. The work was sanctioned by the Ethics Committee Vels 
Institute of Science Technology and Advanced Studies-SPS/IEC/
II/2017/03.
METHODS
The study was designed as prospective observational; single-
blinded. Patients diagnosed at the study center as PTB positive were 
randomized. Two allocation sequences, using blocks of four, were 
created using computer-generated random numbers. Study numbers 
were then assigned consecutively to the generated sequence numbers. 
The two groups are divided; Group A receives normal directly observed 
treatment short course (DOTS) regimen whereas Group B receives 
DOTS regimen with the addition of Zn 15 mg once daily. The sample 
size was calculated for a random sampling of 100 persons with the 
confidence interval of 95% the sample size was found to be 80 with a 
5.75% margin of error.
Outcome measures
The effect was to estimate the serum Zn levels I well established 
PTB patients and to contemplate the efficacy and safety of Zn 
supplementation in PTB patients.
Statistical analysis
Data were analyzed in SPSS for windows version 10.0. Efficacy will be 
analyzed on the basis of Chi-square test while safety will be assessed 
using student t-test with 95% level of significance and “p”<0.05 is 
considered significant.
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Fig. 4 shows the social habits such as alcohol, smokers, and both habits 
among the patients.
Table 4 shows the comorbidity conditions among the patients. HTN 12, 
DM 29, cardiovascular disease (CVD) 6, BA 12, Lymphadenitis 6, HIV 2, 
and none with 40 among the patients.
Fig. 5 shows the comorbidity conditions among the patients. HTN 12, 
DM 29, CVD 06, BA 12, Lymphadenitis 6, HIV 2, and none with 40 among 
the patients.
Fig. 6 shows about the cavitary lesions of the patients 23.75% (19) 
patients were found with cavitary lesions and 61 (76.25%) patients 
were found with non-cavitary lesions.
Table 5 shows the baseline characteristics grouping among the patients. 
Number of zones affected on lungs among the Group A patients is 
2.7±0.6 and in Group B it is 2.9±0.9. Serum Zn levels in Group A were 
0.29±0.26 whereas in Group B the serum Zn levels were 0.32±0.78.
Fig. 7 shows the baseline characteristics grouping among the patients. 
Number of zones affected on lungs among the Group A patients is 
2.7±0.6, and in Group B it is 2.9±0.9. Serum Zn levels in Group A were 
0.29±0.26 whereas in Group B the serum Zn levels were 0.32±0.78.
Table 6 shows the efficacy statement in the patients after 2 months. In 
Group A sputum negative was seen in 27 and Group B sputum negative 
is seen in 36.
Fig. 8 shows the efficacy statement in the patients after 2 months. In 
Group A sputum negative was seen in 27 and Group B Sputum negative 
is seen in 36.
Table 7 shows the efficacy statement in the patients after 6 months. In 
Group A sputum negative was seen in 37 and Group B sputum negative 
was seen in 40. 
RESULTS
Fig. 1 shows the age distribution among the different age groups. The 
number of patients in age group of 18–35 was 21 (26.25%), 36–59 was 
19 (23.75%), 60–85 was 26 (32.5%), and >85 was 14 (17.5%).
Fig. 2 shows the gender distribution among the patients. 56 (70%) 
were male and 24 (30%) were female.
Table 1 shows the economic status of the patients. Patients with poor 
economic status were 27 (33.75%), low- and middle-income were 38 
(47.5%), and middle-income were 15 (18.75%).
Fig. 3 shows the educational qualification in which <10th Grade was 41 
(51.25%), high school 22 (27.5%), diploma 10 (12.5%), UG 6 (7.5%), 
and PG 1 (1.25%).
Table 2 discuss about the area location of the patients. In rural 16 (20%) 
and Urban 64 (80%) were present.
Table 3 describes about the marital status of the patients in the study. 
In the total patients, 51 (63.75%) were married and 29 (36.25%) were 
single.
Fig. 1: Age distribution
Fig. 2: Gender distribution
Fig. 3: Educational qualification
Table 1: Economic status
S. No Economic status Number of patients (%)
1. Poor 27 (33.75)
2. Low middle Income 38 (47.5)
3. Middle Income 15 (18.75)
4. High Income --
Table 2: Location
S. No. Location Number of patients (%)
1. Rural 16 (20)
2. Urban 64 (80)
Table 3: Marital status
S. No. Marital status Number of patients (%)
1. Married 51 (63.75)
2. Single 29 (36.25)
Table 4: Comorbidities
S. No. Comorbidity Number of patients (%)
1. HTN 12 (15)
2. DM 29 (32.5)
3. CVD 06 (7.5)
4. BA 12 (15)
5. Lymphadenitis 06 (7.5)
6. HIV 02 (2.5)
7. None 40 (50)
CVD: Cardiovascular disease
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Fig. 9 shows the efficacy statement in the patients after 6 months. In 
Group A sputum negative was seen in 37 and Group B sputum negative 
was seen in 40.
Table 8 shows the serum Zn levels in the patients of two Groups A and 
B. In Group A after 2 months serum Zn levels were 0.32±0.16. In Group 
B it was 0.86±0.17.
After 6 months, the serum Zn levels in Group A 0.86±0.17 and Group B 
1.21±0.14.
Fig. 10 shows the serum Zn levels in the patients of two Groups A and 
B. In Group A, after 2 months serum Zn levels were 0.32±0.16. In Group 
B, it was 0.86±0.17.
After 6 months the serum Zn levels in Group A 0.86±0.17 and Group B 
1.21±0.14.
Table 9 shows that adverse drug reactions reported in the trial groups. 
There is no much difference between the two groups.WW
DISCUSSION
The above subject area was held out to assess the Zn levels in serum in 
patients diagnosed with PTB. In this, the male population is dominated 
Table 5: Grouping ‑ baseline characteristics
S. No. Parameter (%) Group A n (%)=40 Group B n (%)=40 ‘p’ value
1. Age (mean±SEM) 51.6±3.2 52.1±6.1 0.0932
2. Male n 23 33 0.0762
3. Alcoholic n 10 08 0.0862
4. Smokers n 19 13 0.0652
6. HIV n 01 01 0.0982
7. Cavitary lesions n 11 08 0.0542
8. HTN n 07 05 0.0982
9. DM n 14 15 0.0628
10. BMI (mean±SEM) 19.1±3.2 18.9±2.9 0.0527
11 Serum Zn level (mcg/ml) 0.29±0.26 0.32±0.78 0.05217
12. Number of patients of zones affected on lungs 2.7±0.6 2.9±0.9 0.07421
13. ESR (mm/hr) 39.6±4.8 32.9±6.2 0.05121
14. CRP 5.1±2.7 4.9±2.6 0.07621
ESR: Erythrocyte sedimentation rate, CRP: C-reactive protein, Zn: Zinc
Table 6: Efficacy assessment
After 2 months
Groups Group A Group B p value
Sputum negative 27 36 0.0421*
Sputum positive 13 04 0.0629*
Table 7: Efficacy assesment
After 6 months
Groups Group A Group B p value
Sputum negative 37 40 0.00976
Sputum positive 03 00 0.00971
Table 8: Serum Zn levels
S. No. 2 months 6 months p value
A 0.32±0.16 0.39±0.26 0.0976
B 0.86±0.17 1.21±0.14 0.0217**
p value 0.0216* 0.0010**
Zn: Zinc
Table 9: ADR
S. No. ADR Group A Group B p value
1. Abnormal LFT 06 07 0.0976
2. Nausea 03 02 0.0978
3. Vomiting 06 08 0.0827
4. Constipation 02 06 0.0527
5. GI disturbances 04 01 0.0626
ADR: Adverse drug reactions, LFT: Liver function tests
Fig. 4: Social habits
Fig. 5: Comorbidities
Fig. 6: Cavitary lesions
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among study topics which may be a genetic and community factor, a 
survey conducted in India said that 70% of the study subjects are males 
[10]. A written statement from a study in Indonesia also reported more 
amount of males in the study subjects [11]. In the study subjects, the 
mean age of male patients was 51.62±6.3 years.
Zn levels in the serum were estimated in the study population, and it 
was observed that the patients with PTB had low Zn levels in serum. 
It may be due to the distribution of Zn from plasma to other tissues, 
reduction of the Zn-carrier protein α-macroglobulin in the hepatic 
production and to an increase in the secretion of melatonin that 
transports Zn to the liver.
It was reported that above 89% of patients in the present study had low 
Zn level in serum Lower than the characteristic value (0.29 mcg/ml) [12]. 
In this present work, the average Zn level in serum reported among study 
populations was 0.29±0.26 mcg/ml [13]. The standardized reports are 
entered in some other field. They too reported that the mean serum Zn 
level in the study population was 0.89±0.52 mg/ml and another study 
reported that the average Zn level among pulmonary TB patients was 
9.7±1.8 mmol/L [10].
In our work, there is significant growth in Zn concentrations levels 
in serum occurred in the supplemented groups at 2 and 6 months 
of treatment. Information from the supplementation group showed 
significant growth in plasma Zn concentrations after 2 months, 
but significant growth is entered at the end of treatment in both 
supplemented and non-supplemented participants [14,6]. The 
outcome of symptomatic disease on Zn homeostasis should be taken. 
Higher amount of Zn is taken down in liver, than in serum [15]. The 
supplementation of Zn improved the strength of anti-TB drug at the end 
of the 6 months treatment. During the course of treatment, drug aims 
to kill the active tuberculin bacilli, and the subsequent treatment aims 
to kill resident tuberculin bacilli. The purpose of the DOTS regimen is to 
monitor treatment action and the drug concentration variation changes 
which may be observed in sputum positivity. The result in the Zn group 
was recorded by the more no of patients with sputum negative for 
active bacilli and significantly average lower lesion area in the lungs.
Another survey recorded in India showed that TB treatment with 
four drugs in patients who are sputum-positive TB resulted in 
unacceptably high relapse rates in a period of 3 months [16,17]. Zn 
supplementation showed an effect on treatment outcome in first 2 
months and improvement after 6 months. Basing the results our survey 
suggests that it would be useful to add micronutrients to the current 
TB treatment regimens. Sputum smear conversion was significantly 
faster in the Zn group than in the other group after 6 months of anti-TB 
treatment.
CONCLUSION
By above study and results, we conclude that micronutrient 
supplementation had effect on outcome in earlier sputum conversion at 
the end of 6 months therapy in participants with PTB. The survey also 
says that more patients presented with PTB case present with low Zn 
concentration in serum, which is a factor for estimation of Zn levels in 
serum and attains an instrument in the treating PTB patients. Zn tablet 
is suggested to be an important part for the regimen.
Laboratory estimation of the Zn levels could be employed to evaluate 
the strength of the ongoing anti-tuberculous therapy. Further clinical 
trials with longer study periods are needed to evaluate the efficacy of 
such interventions on treatment issues.
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